Fibrogen, Inc. v. Hangzhou Andao Pharmaceutical LTD.
Opinion
trial_court Opinion
1 2 3 4 UNITED STATES DISTRICT COURT 5 NORTHERN DISTRICT OF CALIFORNIA 6 7 FIBROGEN, INC., Case No. 22-cv-07148-AMO
8 Plaintiff,
ORDER GRANTING IN PART AND
9 v. DENYING IN PART MOTION TO
DISMISS
10 HANGZHOU ANDAO PHARMACEUTICAL LTD., et al., Re: Dkt. Nos. 31, 78, 105 11 Defendants.
12 13 This case is about former employees’ use of an employer’s intellectual property. 14 Defendants Hangzhou Andao Pharmaceutical Ltd., Kind Pharmaceuticals LLC, Dr. Dong Liu, and 15 Dr. Shaojiang Deng’s motion to dismiss was heard before this Court on August 17, 2023. Also 16 pending before the Court is Defendants’ motion for sanctions. Having read the papers filed by the 17 parties and carefully considered their arguments therein and those made at the hearing, as well as 18 the relevant legal authority, the Court hereby GRANTS IN PART AND DENIES IN PART the 19 motion to dismiss and TERMINATES the motion for sanctions, subject to resubmission, for the 20 following reasons. 21 I. Background1 22 Plaintiff FibroGen, Inc. (“FibroGen”) is a…